1
|
Carpenet H, Cuvillier A, Perraud A, Martin O, Champier G, Jauberteau MO, Monteil J, Quelven I. Radiolabelled polymeric IgA: from biodistribution to a new molecular imaging tool in colorectal cancer lung metastases. Oncotarget 2017; 8:85185-85202. [PMID: 29156712 PMCID: PMC5689602 DOI: 10.18632/oncotarget.19616] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/21/2016] [Accepted: 07/03/2017] [Indexed: 11/25/2022] Open
Abstract
By radiolabelling monomeric (m) and polymeric (p) IgA with technetium 99m (99mTc), this study assessed IgA biodistribution and tumour-targeting potency. IgA directed against carcinoembryonic antigen (CEA), a colorectal cancer marker, was selected to involve IgA mucosal tropism. Ig was radiolabelled with 99mTc-tricarbonyl after derivatisation by 2-iminothiolane. 99mTc-IgA was evaluated by in vitro analysis. The biodistributions of radiolabelled anti-CEA mIgA, pIgA and IgG were compared in normal mice. Anti-CEA pIgA tumour uptake was studied in mice bearing the WiDr caecal orthotopic graft. IgA radiolabelling was obtained with a high yield, was stable in PBS and murine plasma, and did not alter IgA binding functionality (Kd ≈ 25 nM). Biodistribution studies in normal mice confirmed that radiolabelled pIgA - and to a lesser extent, mIgA - showed strong and fast mucosal tropism and a shorter serum half-life than IgG. In caecal tumour model mice, evaluation of the anti-CEA-pIgA biodistribution showed a high uptake in lung metastases, confirmed by histological analysis. However, no radioactivity uptake increase in the tumoural caecum was discerned from normal intestinal tissue, probably due to high IgA caecal natural tropism. In microSPECT/CT imaging, 99mTc-IgA confirmed its diagnostic potency of tumour in mucosal tissue, even if detection threshold by in vivo imaging was higher than post mortem studies. Contribution of the FcαRI receptor, studied with transgenic mouse model (Tsg SCID-CD89), did not appear to be determinant in 99mTc-IgA uptake. Pre-clinical experiments highlighted significant differences between 99mTc-IgA and 99mTc-IgG biodistributions. Furthermore, tumoural model studies suggested potential targeting potency of pIgA in mucosal tissues.
Collapse
Affiliation(s)
- Helene Carpenet
- Nuclear Medicine Department, Dupuytren University Hospital, 87042 Limoges, France
- EA 3842 – Cellular Homeostasis and Diseases, Faculty of Medicine, University of Limoges, 87025 Limoges, France
| | | | - Aurélie Perraud
- EA 3842 – Cellular Homeostasis and Diseases, Faculty of Medicine, University of Limoges, 87025 Limoges, France
| | - Ophélie Martin
- UMR CNRS 7276 – CRIBL, University of Limoges, 87025 Limoges, France
| | | | - Marie-Odile Jauberteau
- EA 3842 – Cellular Homeostasis and Diseases, Faculty of Medicine, University of Limoges, 87025 Limoges, France
| | - Jacques Monteil
- Nuclear Medicine Department, Dupuytren University Hospital, 87042 Limoges, France
- EA 3842 – Cellular Homeostasis and Diseases, Faculty of Medicine, University of Limoges, 87025 Limoges, France
- UMR CNRS 7276 – CRIBL, University of Limoges, 87025 Limoges, France
| | - Isabelle Quelven
- Nuclear Medicine Department, Dupuytren University Hospital, 87042 Limoges, France
- EA 3842 – Cellular Homeostasis and Diseases, Faculty of Medicine, University of Limoges, 87025 Limoges, France
- UMR CNRS 7276 – CRIBL, University of Limoges, 87025 Limoges, France
| |
Collapse
|
2
|
Benoist E, Coulais Y, Almant M, Kovensky J, Moreau V, Lesur D, Artigau M, Picard C, Galaup C, Gouin SG. A Click procedure with heterogeneous copper to tether technetium-99m chelating agents and rhenium complexes. Evaluation of the chelating properties and biodistribution of the new radiolabelled glucose conjugates. Carbohydr Res 2011; 346:26-34. [DOI: 10.1016/j.carres.2010.10.011] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/31/2010] [Revised: 10/07/2010] [Accepted: 10/10/2010] [Indexed: 10/18/2022]
|
3
|
Matsumura K, Niki I, Tian H, Takuma M, Hongo N, Matsumoto S, Mori H. Radioimmunoscintigraphy of pancreatic cancer in tumor-bearing athymic nude mice using (99m)technetium-labeled anti-KL-6/MUC1 antibody. ACTA ACUST UNITED AC 2008; 26:133-9. [PMID: 18683568 DOI: 10.1007/s11604-007-0207-6] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022]
Abstract
PURPOSE KL-6 is an extracellular epitope of MUC1, a membrane-penetrating glycoprotein, and its overexpression has been reported in pancreatic cancer. The aim of this study was to examine whether radiolabeled anti-KL-6/MUC1 antibody could be used for molecular imaging of pancreatic cancer in vivo. MATERIALS AND METHODS Anti-KL-6/MUC1 antibody was labeled with 99mTC by the stannous reduction method. Immunoreactivity of the 99mTc-labeled anti-KL-6/MUC1 antibody was evaluated by a whole-cell binding study. In vivo experiments were performed by injecting the 99mTc-labeled anti-KL-6/MUC1 antibody into athymic nude mice bearing the KP-1NL pancreatic cancer cell line. RESULTS A whole-cell binding study showed that the radiolabeled antibody retained its immunoreactivity. On scintigrams, the density of the tumors remained unchanged during the 16-32 h after injection, whereas that of the kidneys decreased time-dependently. The radioactivity levels of the kidneys and tumors were measured densitometrically, and we found that the intensity in the tumors relative to that in the kidneys increased time-dependently. Radioactivity levels were the highest in the blood 32 h after injection, and those in the liver, kidney, lung, and tumor were also rather high. CONCLUSION 99mTc-labeled anti-KL-6/MUC1 antibody appears to be a promising agent as a tumor-specific radiotracer for pancreatic cancer.
Collapse
Affiliation(s)
- Kenji Matsumura
- Department of Radiology, Oita University Faculty of Medicine, Hasama-machi, Yufu 879-5593, Japan
| | | | | | | | | | | | | |
Collapse
|
4
|
Tang B, Yang Z, Huang J, Hao Z, Li W, Cui L, He W. Evaluation of human major histocompatibility complex class I chain-related A as a potential target for tumor imaging. Cancer Lett 2008; 263:99-106. [PMID: 18249063 DOI: 10.1016/j.canlet.2007.12.027] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/25/2007] [Revised: 12/07/2007] [Accepted: 12/14/2007] [Indexed: 02/07/2023]
Abstract
To investigate the feasibility of using human major histocompatibility complex class I chain-related A (MICA) as a target for tumor imaging diagnosis, 10C6, a monoclonal antibody (mAb) that specifically recognizes MICA in vitro, was labeled with (99m)Tc (technetium) and administered into mice bearing MICA-positive human ovarian epithelial carcinoma line SKOV3. Measurement of organ-specific radioactivity showed that tumor accumulated radioactivity continuously, while the uptake in the other organs decreased over time. Scintigram showed that the tumor became clearly visible at 24h post-injection of radio-labeled 10C6 mAb. These results suggest that MICA is a promising target for tumor imaging and mAb 10C6 may be used clinically for early tumor diagnosis.
Collapse
Affiliation(s)
- Bixia Tang
- Department of Immunology, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences & School of Basic Medicine, Peking Union Medical College, China
| | | | | | | | | | | | | |
Collapse
|
5
|
Mukerjee S, McKnight ME, Glassy MC. Immunoscreening protocols for the identification of clinically useful antibodies and antigens. Expert Opin Investig Drugs 2005; 7:373-89. [PMID: 15991979 DOI: 10.1517/13543784.7.3.373] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
The antigen-antibody interaction is a powerful tool for the immuno-screening of several diseases, including cancer and genetic disorders. The high specificity of monoclonal antibodies (mAbs) enables them to target antigens and form complexes that can be detected with enzymes, radionuclides, fluorescent dyes or other markers. The antibody molecule, which has an antigen binding site, can be used as an intact molecule or as a fragment, for example, F(ab)(2), Fab, Fv or scFv. Similarly, the antigen can also be varied. In this review, immuno-screening techniques that can be used to detect clinically relevant antibody-antigen interactions will be discussed.
Collapse
Affiliation(s)
- S Mukerjee
- Novopharm Biotech, Inc., 10246 Parkdale Ave., San Diego, CA 92126, USA
| | | | | |
Collapse
|
6
|
Karube Y, Katsuno K, Ito S, Matsunaga K, Takata J, Kuroki M, Murakami M, Matsuoka Y. Tumor scintigraphy by the method for subtracting the initial image with technetium-99m labeled antibody. Ann Nucl Med 1999; 13:407-13. [PMID: 10656275 DOI: 10.1007/bf03164935] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
Abstract
The method for subtracting the initial image from the localization image was evaluated for radioimmunoscintigraphy of tumors with technetium-99m (Tc-99m) labeled antibodies. Monoclonal antibodies were parental mouse and mouse-human chimeric antibodies to carcinoembryonic antigen (CEA), designated F11-39 and ChF11-39, respectively, both of which have been found to discriminate CEA in tumor tissues from the CEA-related antigens. After reduction of the intrinsic disulfide bonds, these antibodies were labeled with Tc-99m. In vivo studies were performed on athymic nude mice bearing the human CEA-producing gastric carcinoma xenografts. Though biodistribution results showed selective and progressive accumulation of Tc-99m labeled antibodies at the tumor site, high radioactivity in blood was inappropriate for scintigraphic visualization of the tumors within a few hours. We examined the subtraction of the initial Tc-99m image from the Tc-99m localization image after a few hours. Subtracted images of the same count reflected the in vivo behavior of the Tc-99m radioactivity. The subtracted scintigrams revealed excellent tumor images with no significant extrarenal background. Visualization of the tumor site was dependent on antigen-specific binding and nonspecific exudation. These results demonstrate that a method of subtraction of the initial image may serve as a potentially useful diagnostic method for an abnormal site for agents with a low pharmacokinetic value.
Collapse
Affiliation(s)
- Y Karube
- Faculty of Pharmaceutical Sciences, Fukuoka University, Japan.
| | | | | | | | | | | | | | | |
Collapse
|